ArticleNature biotechnology2021
Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters.
Article in Nature biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Single cell multiomics unravel the transcription networks controlling the different EMT tumor states.Nature communications · 2026Article
- Charting single-cell lineages with synthetic and natural barcodes.Nature reviews. Genetics · 2026Review
- Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance.Genome biology · 2026Article
- Review
- A multi-kingdom genetic barcoding system for precise clone isolation.Nature biotechnology · 2026Article
- Strength through diversity: how cancers thrive when clones cooperate.Molecular oncology · 2026Review
- Multiplexed enrichment and tracking of lineages with CloneSweeper.bioRxiv : the preprint server for biology · 2026Article
- BAF complex-independent gene activation by SS18::SSX.bioRxiv : the preprint server for biology · 2026Article
- Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy.Science advances · 2025Article
- Stereotyped Subclones Revealed by High-Density Single-Cell Lineage Tracing Support Robust Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Quantifying the intra- and inter-species community interactions in microbiomes by dynamic covariance mapping.Nature communications · 2025Article
- EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer.Cancer cell international · 2025Article
- Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer.NPJ systems biology and applications · 2025Article
- Recording Lineage History with Cellular Barcodes in the Mammary Epithelium and in Breast Cancer.Advances in experimental medicine and biology · 2025Review
- Functional Lineage Tracing Using CaTCH.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Single-Cell Lineage Tracing and Clonal State-Fate Analysis.Methods in molecular biology (Clifton, N.J.) · 2025Article
- An expanded view of cell competition.Development (Cambridge, England) · 2024Review
- Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.Nature reviews. Cancer · 2024Review
- Synthetic DNA barcodes identify singlets in scRNA-seq datasets and evaluate doublet algorithms.Cell genomics · 2024Article
- Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
We developed a functional lineage tracing tool termed CaTCH (CRISPRa tracing of clones in heterogeneous cell populations). CaTCH combines precise clonal tracing of millions of cells with the ability to retrospectively isolate founding clones alive before and during selection, allowing functional experiments. Using CaTCH, we captured rare clones representing as little as 0.001% of a population and investigated the emergence of resistance to targeted melanoma therapy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.